Pfizer (PFE) Status Update summary

Strategic Focus and Oncology Strategy

• ADCs are prioritized for their modularity, scalability, and broad deployment potential, leveraging expertise from both Pfizer and Seagen to address multiple cancer types.

• The oncology strategy integrates small molecules, biologics, and ADCs, with a focus on next-generation ADCs and non-ADC biologics targeting breast, genitourinary, hematology-oncology, and thoracic cancers.

• Pfizer is building on its established presence to address unmet medical needs across the care continuum.

ADC Platform, Development, and Mechanism

• Integration of Pfizer and Seagen strengths creates a global leader in ADC development, combining expertise in small molecules, protein engineering, and ADC discovery.

• ADCs consist of an antibody, a payload, and a linker, delivering cytotoxic molecules selectively to cancer cells, with advances in target identification, linker design, and payload engineering.

• Vedotin (MMAE) ADCs induce direct cytotoxicity, cell cycle arrest, microtubule disruption, and immunogenic cell death, supporting combinations with immune checkpoint inhibitors.

Clinical Performance and Portfolio Highlights

• Combination regimens, such as PADCEV plus pembrolizumab, have shown significant survival benefits, including nearly 50% reduction in risk of death versus chemotherapy in advanced urothelial carcinoma.

• Pfizer has five FDA-approved ADCs and one additional product approved in China, with a robust pipeline targeting novel mechanisms and diversified payload technologies.

• The pipeline features novel ADCs like disitamab vedotin (DV), sigvotatug vedotin (SV), and PD-L1V, with multiple phase III studies planned or underway and new indications anticipated in 2025.